Tejpar, Bertagnolli, Bosman et al. 403 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 factors for Dukes’ stage B colorectal cancer. Eur J Cancer 2000;36:1008 – 1015. Zauber NP, Wang C, Lee PS et al. Ki-ras gene mutations, LOH of the APC and DCC genes, and microsatellite instability in primary colorectal carci- noma are not associated with micrometastases in pericolonic lymph nodes or with patients’ survival. J Clin Pathol 2004;57:938 –942. Tortola S, Marcuello E, González I et al. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J Clin Oncol 1999;17:1375–1381. Esteller M, González S, Risques RA et al. K-ras and p16 aberrations con- fer poor prognosis in human colorectal cancer. J Clin Oncol 2001;19:299 – 304. Fuchs C, Ogino S, Meyerhardt JA et al. KRAS mutation, cancer recur- rence, and patient survival in stage III colon cancer: Findings from CALGB 89803 [abstract 4037]. J Clin Oncol 2009;27(15 suppl):177s. Lièvre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374 –379. Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in met- astatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230 –3237. De Roock W, Piessevaux H, De Schutter J et al. KRAS wild-type state predicts survival and is associated to early radiological response in meta- static colorectal cancer treated with cetuximab. Ann Oncol 2008;19:508 – 515. Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360: 1408 –1417. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663– 671. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626 –1634. Rajagopalan H, Bardelli A, Lengauer C et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002;418:934. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949 –954. Ikenoue T, Hikiba Y, Kanai F et al. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res 2003;63:8132– 8137. Fransén K, Klintenäs M, Osterström A et al. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004;25:527–533. Samowitz WS, Sweeney C, Herrick J et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005;65:6063– 6069. Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal can- cer. N Engl J Med 2009;361:98 –99. Ogino S, Nosho K, Kirkner GJ et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90 –96. Pinedo HM, Peters GF. Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 1988;6:1653–1664. dylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 1974;13: 471– 481. 100 Berger SH, Jenh CH, Johnson LF et al. Thymidylate synthase overproduc- tion and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol 1985;28:461– 467. 101 Edler D, Glimelius B, Hallström M et al. Thymidylate synthase expression in colorectal cancer: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002;20:1721– 1728. 102 Johnston PG, Fisher ER, Rockette HE et al. The role of thymidylate syn- thase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994;12:2640 –2647. 103 Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: A systematic review and meta-analy- sis. J Clin Oncol 2004;22:529 –536. 104 Sakamoto J, Hamashima H, Suzuki H et al. Thymidylate synthase expres- sion as a predictor of the prognosis of curatively resected colon carcinoma in patients registered in an adjuvant immunochemotherapy clinical trial. Oncol Rep 2003;10:1081–1090. 105 Soong R, Shah N, Salto-Tellez M et al. Prognostic significance of thymi- dylate synthase, dihydropyrimidine dehydrogenase and thymidine phos- phorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol 2008;19:915– 919. 106 Kornmann M, Schwabe W, Sander S et al. Thymidylate synthase and di- hydropyrimidine dehydrogenase mRNA expression levels: Predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003;9:4116 – 4124. 107 Sinicrope FA, Rego RL, Halling KC et al. Thymidylate synthase expres- sion in colon carcinomas with microsatellite instability. Clin Cancer Res 2006;12:2738 –2744. 108 Westra JL, Hollema H, Schaapveld M et al. Predictive value of thymidy- late synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. Ann On- col 2005;16:1646 –1653. 109 Salonga D, Danenberg KD, Johnson M et al. Colorectal tumors respond- ing to 5-fluorouracil have low gene expression levels of dihydropyrimi- dine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000;6:1322–1327. 110 Leichman CG, Lenz HJ, Leichman L et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal can- cer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997;15:3223–3229. 111 Morganti M, Ciantelli M, Giglioni B et al. Relationships between pro- moter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. Eur J Cancer 2005;41:2176 –2183. 112 Mandola MV, Stoehlmacher J, Zhang W et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 2004; 14:319 –327. 113 Lurje G, Zhang W, Yang D et al. Thymidylate synthase haplotype is as- sociated with tumor recurrence in stage II and stage III colon cancer. Phar- macogenet Genomics 2008;18:161–168. 114 Iacopetta B, Grieu F, Joseph D et al. A polymorphism in the enhancer re- gion of the thymidylate synthase promoter influences the survival of colo- rectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001;85: 827– 830. Santi DV, McHenry CS, Sommer H. Mechanism of interaction of thymi- 115 Hitre E, Budai B, Adleff V et al. Influence of thymidylate synthase gene www.TheOncologist.com